Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Depreciation and Depletion (2022 - 2025)

Historic Depreciation and Depletion for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $44599.0.

  • bioAffinity Technologies' Depreciation and Depletion rose 1019.72% to $44599.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $175636.0, marking a year-over-year decrease of 3854.8%. This contributed to the annual value of $162332.0 for FY2024, which is 3034.87% down from last year.
  • Per bioAffinity Technologies' latest filing, its Depreciation and Depletion stood at $44599.0 for Q3 2025, which was up 1019.72% from $44468.0 recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' Depreciation and Depletion ranged from a high of $166284.0 in Q4 2023 and a low of $800.0 during Q3 2022
  • In the last 4 years, bioAffinity Technologies' Depreciation and Depletion had a median value of $40243.0 in 2024 and averaged $37287.2.
  • As far as peak fluctuations go, bioAffinity Technologies' Depreciation and Depletion soared by 553687.5% in 2023, and later tumbled by 7425.73% in 2024.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Depreciation and Depletion stood at $7282.0 in 2022, then surged by 2183.49% to $166284.0 in 2023, then plummeted by 74.26% to $42806.0 in 2024, then increased by 4.19% to $44599.0 in 2025.
  • Its last three reported values are $44599.0 in Q3 2025, $44468.0 for Q2 2025, and $43763.0 during Q1 2025.